40 related articles for article (PubMed ID: 16723621)
1. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib.
Lei T; Tan F; Hou Z; Liu P; Zhao X; Liu H
Front Oncol; 2020; 10():596500. PubMed ID: 33552970
[TBL] [Abstract][Full Text] [Related]
2. Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).
Cameron S; Gieselmann M; Blaschke M; Ramadori G; Füzesi L
Int J Clin Exp Pathol; 2014; 7(7):3563-79. PubMed ID: 25120735
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.
Poggi A; Zocchi MR
Oncoimmunology; 2012 Mar; 1(2):214-216. PubMed ID: 22720246
[TBL] [Abstract][Full Text] [Related]
4. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
Catellani S; Pierri I; Gobbi M; Poggi A; Zocchi MR
PLoS One; 2011 Apr; 6(4):e18925. PubMed ID: 21533122
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.
Ott PA; Adams S
Immunotherapy; 2011 Feb; 3(2):213-27. PubMed ID: 21322760
[TBL] [Abstract][Full Text] [Related]
6. Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Kao J; Ko EC; Eisenstein S; Sikora AG; Fu S; Chen SH
Crit Rev Oncol Hematol; 2011 Jan; 77(1):12-9. PubMed ID: 20304669
[TBL] [Abstract][Full Text] [Related]
7. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.
Malmberg KJ; Bryceson YT; Carlsten M; Andersson S; Björklund A; Björkström NK; Baumann BC; Fauriat C; Alici E; Dilber MS; Ljunggren HG
Cancer Immunol Immunother; 2008 Oct; 57(10):1541-52. PubMed ID: 18317755
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
Carpenter PA; Snyder DS; Flowers ME; Sanders JE; Gooley TA; Martin PJ; Appelbaum FR; Radich JP
Blood; 2007 Apr; 109(7):2791-3. PubMed ID: 17119111
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells and innate defense against tumor cells.
Ullrich E; Ménard C; Flament C; Terme M; Mignot G; Bonmort M; Plumas J; Chaperot L; Chaput N; Zitvogel L
Cytokine Growth Factor Rev; 2008 Feb; 19(1):79-92. PubMed ID: 18155952
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate--uncovering a fast track to adaptive immunity.
Smyth MJ
N Engl J Med; 2006 May; 354(21):2282-4. PubMed ID: 16723621
[No Abstract] [Full Text] [Related]
11. [Innate defence against tumor cells: the killer cell IKDC].
Chaput N; Taieb J; Zitvogel L
Bull Cancer; 2006 May; 93(5):449-51. PubMed ID: 16777622
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L
Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
[TBL] [Abstract][Full Text] [Related]
14. Is it a DC, is it an NK? No, it's an IKDC.
Shortman K; Villadangos JA
Nat Med; 2006 Feb; 12(2):167-8. PubMed ID: 16462794
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
